GaryG Posted November 27, 2020 Share Posted November 27, 2020 Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target [1]. In presenting positive data from a Phase I dose-escalation study of AMG 510, an oral small molecule inhibitor of KRAS G12C. AMG 510 achieved a 50% response rate among non-small cell lung cancer (NSCLC) patients expressing the KRAS G12C mutation. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.